Farletuzumab has demonstrated anti-tumor activity and favorable toxicity in preclinical evaluation. This phase I dose-escalation study was conducted to determine the safety of weekly intravenous farletuzumab and establish the maximum tolerated dose. We demonstrated that farletuzumab possesses an acceptable toxicity profile and, thus, may be a disease management option for heavily pre-treated patients with Epithelial Ovarian Cancer. 
INTRODUCTION
Epithelial ovarian cancer (EOC) is the eighth most-common cancer and fifth most-common cause of cancer deaths among women in the US (1) . First-line platinum-based chemotherapy achieves clinical remission in the majority of patients with debulked EOC (2) , but the disease will recur in most. The five-year survival rate is approximately 45% (3) . Therapies with additional clinical benefits are needed.
Folate receptor alpha (FRα) is a membrane-bound protein with high affinity for binding and transporting physiologic levels of folate into cells (4) . FRα expression is upregulated in a range of human cancer types, including ovarian, breast, brain, lung, and colorectal cancers (5, 6) .
FRα is upregulated in approximately 90% of EOCs and correlates with stage and grade (7).
Furthermore, overexpression confers a growth advantage in tumorigenic ovarian cells in vitro Patients with stable disease (SD) or better were permitted to continue treatment at the investigator's discretion. Any treatment-related adverse event (TRAE) ≥Grade 3 constituted DLT. If DLT was observed within 5 weeks of initiating therapy, up to 6 patients were to be entered at that dose level. Dose escalation was permitted only after all patients in the cohort had completed the 4 weekly infusions plus 2 weeks' follow-up. Intra-patient dose escalation was not permitted. The MTD was defined as one dose level below which 2 or more of 6 patients experienced DLT.
Research. Board approval at MSKCC and all patients were required to provide written informed consent.
Patients were ineligible if they had central nervous system tumor involvement, evidence of other active malignancy, or ascites ≥500 mL. Patients with active serious systemic disease, including asthma or heart disease, were excluded. Chemotherapy, biologic therapy, or immunotherapy within 3 weeks before enrollment, or a history of immune or allergic reaction or documented HAHA were also exclusion criteria.
Safety Analysis
Safety data were recorded throughout the treatment period and for 2 weeks after the last dose. 
Radio-imaging substudy
Research. In chelated with 5 mg DOTA-farletuzumab coadministered with cold antibody, and serial blood sampling was performed, and is further detailed in a prior publication (10).
Efficacy Analysis
Disease status characterized using RECIST criteria was noted and serum CA-125 measured at the screening and final visits. Computerized tomography (CT) was preferred for lesion evaluation, but magnetic resonance imaging or clinical evidence of progression were also acceptable. 
Accrual time and Statistical Analysis

RESULTS
Patients and Treatment Characteristics
A total of 25 patients received at least one IV infusion and were included in the safety, efficacy, and PK analyses. The median age was 56 years (44-79) and the median time since diagnosis was 59.9 months (10-200) ( Table 1 There were no serious or severe (≥Grade 3) TRAEs and no treatment-related myelotoxicity or neurotoxicity. The most common TRAEs were HSRs (15 patients; 60%), fatigue (12 patients; 48%), and diarrhea (4 patients; 16%). There were no apparent dose-related trends in AE frequency or severity and no TRAEs required treatment discontinuation. Farletuzumab was not associated with clinically significant changes in cardiac, pulmonary, or renal function.
Research. 
Pharmacokinetics and Biodistribution
Mean farletuzumab concentration-time profiles for the 7 dose levels at each weekly infusion are presented in Figure 1 . The sampling scheme was not optimized for accurate determination of a long half-life, and resulted in difficulties observing a well-defined terminal phase to many of the concentrationtime profiles. Where estimated, the mean terminal farletuzumab t ½ values are shown in Table 3 .
The estimated day 22 t 1/2 values were typically higher than the corresponding day 1 estimates across the dose range. Following multiple weekly infusions, the t 1/2 estimates ranged from 121 to 260 hours, indicating a slow clearance of farletuzumab. 
Anti-tumor Activity
Nine (36%) patients had SD, and the remaining 15 patients had progression as the best response according to RECIST. One patient was not evaluable by RECIST. Three of the patients with SD were approved by the investigator to receive farletuzumab for up to 3 total cycles, with mean decreases in target lesion size of 3% to 17% from baseline to end of cycle 1 noted (after 4 doses). 120.9 [1] 76.3 [3] 86.3 [2] 135.1 [3] 146.4 [1] 77.0 [2] 108.6 [2] 90.3 [3] 131.9 [2] 79.5 [3] 100.2 [3] 117.9 [1] 135.3 [2] -92.3 [1] 84.1 [1] 174.8 [3] 97.1 [3] 131.4 [1] 135 
